CDC director tells Senate she is 'cautiously optimistic' about state of fight against COVID-19 Roll call: How Big Pharma is charting a path back to the office in 2021 BerGenBio fails COVID-19 trial, makes post hoc case for program COVID-19 tracker: Emergent reveals cause of J&J manufacturing error; Lilly links another baricitinib licensing deal COVID-19 vaccine makers, after rejecting controversial IP proposal, lay out their own plan to improve global supplies Biopharma R&D 'surged' in 2020, but trial productivity levels a mixed bag: report American skeptics fuel ongoing pharma 'trust deficit' despite pandemic gains, research finds CNN Report: CHS sued nearly 19,000 patients for unpaid medical bills since start of pandemic UPDATED Coronavirus tracker: 10M shots delivered by HHS-backed community health centers CytoDyn begs investors to stop trashing FDA in bizarre call after agency's public smackdown Emergent execs set to testify before some of the same lawmakers its political spending helped elect: report Featured Story | By Robert King CDC Director Rochelle Walensky told senators she was "cautiously optimistic" on where things stand in the fight against the pandemic but worries about variants remain. read more |
| |
|---|
|
Top Stories By Fraiser Kansteiner With vaccines putting COVID-19 on the defense in the U.S., drugmakers are grappling with the question of when, how and whether employees might return to the office. The short answer? Consensus says fully in-person work is going the way of the dinosaur. read more By Nick Paul Taylor A phase 2 clinical trial of BerGenBio’s bemcentinib in hospitalized COVID-19 patients has missed its primary endpoint. The AXL inhibitor failed to accelerate time to sustained clinical improvement over standard of care, but BerGenBio identified a subgroup analysis of a secondary endpoint as a reason to continue development. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner Emergent BioSolutions has been in the spotlight ever since it ruined up to 15 million doses of Johnson & Johnson's COVID-19 vaccine. Now, the company says its intense efforts to scale up that shot and another from AstraZeneca caused the mishap. Plus more. read more By Kevin Dunleavy Two weeks after the Biden administration voiced support for lifting patent protections for COVID-19 vaccines, a worldwide trade association representing the pharmaceutical industry has formulated a plan to address the problem of inequities in vaccine availability. read more By Ben Adams A major global pandemic was not enough to stop surging rates of biopharma research and development, but trial productivity still remains below the long-term average. read more By Beth Snyder Bulik Despite the pandemic and its promise of a relationship reset, half of Americans still don’t trust pharma companies, according to Deloitte studies in four different countries. But a much larger 80% of people in the other three countries—India, South Africa and the U.K.—said they trusted or were neutral toward drugmakers. read more By Robert King Community Health Systems filed at least 19,000 lawsuits against patients for unpaid medical bills since the start of the pandemic last March, a new CNN investigation found. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Annalee Armstrong CytoDyn President and CEO Nader Pourhassan begged his investors to stop trashing the FDA after the agency issued a rare public rebuke over the company’s public statements on a pair of failed COVID-19 clinical trials. “You can throw all kinds of eggs and tomatoes, whatever you like, at me. I deserve it,” Pourhassen said. “But please don’t do that to the regulatory agency.” read more By Fraiser Kansteiner Emergent BioSolutions' influence within the federal government has been placed under a spotlight ever since a manufacturing flub forced the contractor to discard millions of doses of Johnson & Johnson's COVID-19 vaccine. Now, two of the company's top execs are headed to Congress to discuss that work before some of the same lawmakers it helped elect. read more |
